A detailed history of Silvercrest Asset Management Group LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Silvercrest Asset Management Group LLC holds 13,759 shares of VRTX stock, worth $6.91 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares
13,759
Previous 27,518 50.0%
Holding current value
$6.91 Million
Previous $12.9 Million 50.0%
% of portfolio
0.05%
Previous 0.05%

Shares

22 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$392.81 - $485.53 $5.4 Million - $6.68 Million
-13,759 Reduced 50.0%
13,759 $6.45 Million
Q2 2024

Aug 14, 2024

BUY
$392.81 - $485.53 $5.4 Million - $6.68 Million
13,759 Added 100.0%
27,518 $12.9 Million
Q1 2024

May 15, 2024

SELL
$407.69 - $446.08 $8,153 - $8,921
-20 Reduced 0.15%
13,759 $5.75 Million
Q4 2023

Feb 14, 2024

SELL
$343.0 - $410.68 $162,239 - $194,251
-473 Reduced 3.32%
13,779 $5.61 Million
Q3 2023

Nov 14, 2023

BUY
$338.18 - $362.46 $84,545 - $90,615
250 Added 1.79%
14,252 $4.96 Million
Q2 2023

Aug 14, 2023

BUY
$314.42 - $351.91 $183,306 - $205,163
583 Added 4.34%
14,002 $4.93 Million
Q1 2023

May 15, 2023

SELL
$283.23 - $323.1 $2,832 - $3,231
-10 Reduced 0.07%
13,419 $4.23 Million
Q4 2022

Feb 14, 2023

SELL
$285.76 - $321.48 $14,002 - $15,752
-49 Reduced 0.36%
13,429 $3.88 Million
Q3 2022

Nov 14, 2022

SELL
$273.83 - $305.53 $10,953 - $12,221
-40 Reduced 0.3%
13,478 $3.9 Million
Q2 2022

Aug 15, 2022

SELL
$234.96 - $292.55 $131,107 - $163,242
-558 Reduced 3.96%
13,518 $3.81 Million
Q1 2022

May 16, 2022

BUY
$221.42 - $260.97 $1,328 - $1,565
6 Added 0.04%
14,076 $3.67 Million
Q1 2021

May 17, 2021

SELL
$207.02 - $241.31 $137,875 - $160,712
-666 Reduced 4.52%
14,070 $3.02 Million
Q4 2020

Feb 16, 2021

BUY
$207.01 - $276.09 $144,907 - $193,262
700 Added 4.99%
14,736 $3.48 Million
Q1 2020

May 15, 2020

BUY
$199.77 - $247.81 $123,657 - $153,394
619 Added 4.61%
14,036 $3.34 Million
Q2 2019

Aug 14, 2019

BUY
$164.61 - $190.37 $295,145 - $341,333
1,793 Added 15.42%
13,417 $2.46 Million
Q1 2019

May 15, 2019

SELL
$163.73 - $194.7 $8,022 - $9,540
-49 Reduced 0.42%
11,624 $2.14 Million
Q4 2018

Feb 14, 2019

BUY
$151.91 - $192.21 $7,443 - $9,418
49 Added 0.42%
11,673 $1.93 Million
Q3 2018

Nov 14, 2018

BUY
$167.73 - $192.74 $9,225 - $10,600
55 Added 0.48%
11,624 $2.24 Million
Q2 2018

Aug 14, 2018

BUY
$145.72 - $169.96 $259,235 - $302,358
1,779 Added 18.17%
11,569 $1.97 Million
Q1 2018

May 15, 2018

SELL
$151.6 - $177.13 $35,322 - $41,271
-233 Reduced 2.32%
9,790 $1.6 Million
Q4 2017

Feb 14, 2018

BUY
$137.28 - $155.55 $5,903 - $6,688
43 Added 0.43%
10,023 $1.5 Million
Q3 2017

Nov 14, 2017

BUY
$148.13 - $162.24 $1.48 Million - $1.62 Million
9,980
9,980 $1.52 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $129B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Silvercrest Asset Management Group LLC Portfolio

Follow Silvercrest Asset Management Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Silvercrest Asset Management Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Silvercrest Asset Management Group LLC with notifications on news.